Immix Biopharma is a clinical-stage biopharmaceutical company that develops tissue-specific therapeutics for oncology and inflammation. The company's focus is on developing IMX-110 for soft tissue sarcoma and solid tumors, IMX-111 for colorectal cancers and IMX-120 for ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors.